EU Involvement

Eligibility for Involvement in EMA Activities

This EMA working party serves as a platform for exchange and discussion of issues of common interest between the EMA and organisations of healthcare professionals.

In late 2021, the EANM has applied for eligibility involvement in EMA activities, which is currently under evaluation.

The EMA HCPWP was established in 2013 and sets out to “provide recommendations to the EMA and its human scientific committees on all matters of interest in relation to medicines”, following a set of clear objectives.

A work plan for the years 2019-2022 has been developed outlining the specific areas of work of the EMA HCPWP.

Financial assessment

As part of the evaluation of the EANM’s eligibility for involvement in the activities of EMA, the following financial information is provided for EMA’s assessment (data pertaining to the financial year 2020):

Split of non-industry income
(in % of total income)

  • Royalties scientific journals: 2.82%
  • Membership fees: 13.08%
  • Registration fees: 29.05%
  • Donations: 0.98%
  • EU project funding: 0.47%
  • Other income: 2.48%

Split of industry income
(in % of total income)

  • Congress and educational events:  44.03%
  • Corporate membership: 7.39%

The highest contribution from a single company is 5.50% of the overall income.

The overall proportion of industry vs non-industry income in 2020 was 51.42% vs 48.95%.

It has to be noted that the ongoing pandemic and the need to cancel physical events have had a significant impact on the EANM’s finances in the past two years. Due to the decrease in turnover (e.g. registration fees from individual participants), the percentages of the various types of income changed substantially.

Industry partners 2020

The following companies provided financial contributions to the EANM.

AAA
ABX CRO
Alliance Medical
Avid Radiopharmaceuticals (Lilly)
Avid Radiopharmaceuticals Inc.
Bayer Healthcare Pharmaceuticals, Inc
Biocompatibles
Blue Earth Diagnostic Ltd
Boston Scientific International
Bracco Diagnostics
Bruker Biospin
CIS Bio
Comecer SpA
Cyclomedica Europe Ltd
Dosisoft
DSD Pharma
Eckert&Ziegler
Eczacibasi-Monrol Nuclear Products Co.
GE Healthcare
GE Medical
Hermes Medical
IAEA MTBF
IBA S.A.
Isotope Technologies Dresden GmbH
Isotopia Molecular Imaging Ltd.
ITG Isotope
ITM Oncologics
JSC Isotope
Lemer Pax
Medi Radiopharma
Mediso
MiE Medical Imaging Electronics GmbH
Milabs
MiM software
Molecubes NV
MR Solutions
NRG Advanced Nuclear Medicine
OncoBetaGmbH
PBL S.r.l.
Philips
PMB-Alcen
Point Biopharma
Polatom
Radon Saglik
RI-Te Radiation Imaging Technologies
Rotop
Shine Medical Technologies LLC
Siemens Healthineers
Sirtex Medical Europe
Spectrum Dynamics
Sumitomo Heavy Industries
Telix Pharmaceuticals
TEMA Synergi SpA
Terumo
The Oncidium Foundation
Triskem international
US Dept of Energy Isotope Program
Van Gahlen
Wallonia Export & Investment
Zionexa

This website uses cookies. Learn more